781
edits
Changes
no edit summary
=== <span style="color:#0000b2"> Switching from long acting injectables to long acting injectables with a different active substance </span> ===
Instructions for switching between two depots are provided on this page. <br>
Please exercise caution when considering a switch between depots containing different active substances (e.g., switching from olanzapine depot to paliperidone depot). <br>
'''We strongly recommend initially switching to the oral form of the medication before transitioning to the depot. ''' <br>Introducing a depot medication that contains a new active substance may lead to adverse events related to the new drug. Due to the long half-life of depot antipsychotics, these side effects can persist for an extended period. <br>Once the depot is administered, it is not possible to remove the drug from the system; <br>the only way to manage side effects (if possible) is to add a new medication that counteracts them, which may carry its own risks and side effects. <br>In addition, after administration of a new depot a new steady state will be reached after months. <br>It is therefore not possible to optimize dosing in relation to effect on short term.<br>
<br>
==== <span style="color:#ff0000">In cases where a switch from depot to depot is unavoidable, the following protocol can be used:<br> </span> ====
* Add 21 days to the date you would normally administer the Risperdal Consta injection, and on that day, give the maintenance dose of the new depot.<br>
* Do not administer any loading doses.<br>
<br>
2. Switching to Risperdal Consta from another depot:<br>
* Administer Risperdal Consta 21 days before the next scheduled dose of the current depot.<br>
* Do not administer any loading doses.<br>